Answers are grounded in this paper and cite their sources.
IP RIT ¹³¹I-omburtamab was well tolerated with minimal toxicities. Radiation exposure to normal organs was low, making combination therapy with other anticancer therapies feasible.
No takes yet. Share an insight, caveat, or question.
Modak et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: